Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3428 - Intratumoral administration of pro-inflammatory allogeneic , "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Clinical Research

Tumour Site

Presenters

Alex Karlsson-Parra

Citation

Annals of Oncology (2018) 29 (suppl_8): viii133-viii148. 10.1093/annonc/mdy279

Authors

A. Karlsson-Parra, G. Fotaki, D. Yu, M. Essand

Author affiliations

  • Immunology, Genetics And Pathology, Uppsala University, 75185 - Uppsala/SE
More

Resources

Abstract 3428

Background

Activated NK-cells are known to play immune-regulatory “helper” functions, being able to recruit and activate “bystander” DCs and to promote cross-presentation of cell-associated antigens to CD8+ T cells by producing IFN-γ and TNF-α. We have recently shown that intratumoral administration of pro-inflammatory allogeneic mouse DCs (alloDCs) induce NK-cell recruitment and that human GMP-produced human alloDCs (ilixadencel) used in clinical trials (NCT00625755, NCT01974661, NCT02686944, NCT02432846), promote enhanced cytotoxicity and strong IFN-γ production in allogeneic NK-cells in vitro. Furthermore, co-culture of ilixadencel with allogeneic PBMCs leads to a pro-inflammatory environment inducing maturation and strongly enhanced cross-presentation in "bystander" DCs. Here we investigated the anti-tumor effect of intratumorally administered pro-inflammatory mouse alloDCs as monotherapy and in combination with anti-PD-1 or anti-CD137.

Methods

AlloDCs were produced from C57BL/6 mice and activated with a cocktail consisting of polyI:C, R848 and IFN-γ. After cryopreservation and subsequent thawing the cells were injected intratumorally 2 or 3 times starting at day 14 post subcutaneous CT-26 tumor cell inoculation in Balb/C mice. AlloDCs were given as monotherapy or in combination with anti-PD-1 or anti-CD137. The studies were conducted at Charles River Laboratories, Morrisville, NC, USA.

Results

AlloDCs did not significantly delay tumor progression, likewise did not anti-PD-1. Combined treatment with alloDCs/anti-PD-1 significantly delayed tumor progression, while treatment with intratumoral administrations of polyI:C combined with anti-PD-1 showed no significant delay. Anti-CD137 treatment significantly delayed tumor progression and also induced one complete (10%) tumor response. Notably, the combination of alloDCs with anti-CD137 induced a highly significant anti-tumor synergy, including complete tumor eradication in 3 out of 9 mice (33%).

Conclusions

Intratumoral administration of allogeneic pro-inflammatory DCs induces a synergistic anti-tumor response when combined with systemic anti-PD-1 or anti-CD137 treatment.

Clinical trial identification

Legal entity responsible for the study

Immunicum AB, Gothenburg, Sweden.

Funding

Immunicum AB, Gothenburg, Sweden.

Editorial Acknowledgement

Disclosure

A. Karlsson-Parra: Ownership of stocks in Immunicum AB; Employee: Immunicum. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.